BioNTech Announces Appointment of Ramón Zapata to Management Board as Chief Financial Officer
BioNTech (NASDAQ: BNTX) has appointed Ramón Zapata-Gomez as its new Chief Financial Officer, effective July 1, 2025. Zapata will succeed Jens Holstein, who will retire as planned on June 30, 2025. Zapata joins from Novartis AG, where he served as CFO of their global biomedical research organization since 2022.
With over 25 years of experience in pharmaceutical and consumer goods industries, Zapata brings extensive expertise in finance, M&A, and digital transformations. His appointment aligns with BioNTech's strategy to become a multi-product oncology company. In his new role, Zapata will focus on optimizing financial infrastructure, performance in key markets, and driving cost-effective value generation as the company prepares for oncology product launches.
BioNTech (NASDAQ: BNTX) ha nominato Ramón Zapata-Gomez come nuovo Chief Financial Officer, a partire dal 1° luglio 2025. Zapata succederà a Jens Holstein, che andrà in pensione come previsto il 30 giugno 2025. Zapata proviene da Novartis AG, dove dal 2022 ha ricoperto il ruolo di CFO dell'organizzazione globale di ricerca biomedica.
Con oltre 25 anni di esperienza nei settori farmaceutico e dei beni di consumo, Zapata porta con sé una vasta competenza in ambito finanziario, fusioni e acquisizioni, e trasformazioni digitali. La sua nomina è in linea con la strategia di BioNTech di diventare un'azienda oncologica con più prodotti. Nel suo nuovo ruolo, Zapata si concentrerà sull'ottimizzazione dell'infrastruttura finanziaria, sulle performance nei mercati chiave e sulla generazione di valore efficiente in vista del lancio di prodotti oncologici.
BioNTech (NASDAQ: BNTX) ha nombrado a Ramón Zapata-Gomez como su nuevo Director Financiero, con efecto a partir del 1 de julio de 2025. Zapata reemplazará a Jens Holstein, quien se retirará según lo planeado el 30 de junio de 2025. Zapata proviene de Novartis AG, donde desde 2022 se desempeñó como CFO de su organización global de investigación biomédica.
Con más de 25 años de experiencia en las industrias farmacéutica y de bienes de consumo, Zapata aporta un amplio conocimiento en finanzas, fusiones y adquisiciones, y transformaciones digitales. Su nombramiento está alineado con la estrategia de BioNTech de convertirse en una compañía oncológica con múltiples productos. En su nuevo rol, Zapata se enfocará en optimizar la infraestructura financiera, el desempeño en mercados clave y en impulsar la generación de valor rentable mientras la empresa se prepara para el lanzamiento de productos oncológicos.
BioNTech (NASDAQ: BNTX)는 2025년 7월 1일부터 Ramón Zapata-Gomez를 새로운 최고재무책임자(CFO)로 임명했습니다. Zapata는 2025년 6월 30일 예정대로 은퇴하는 Jens Holstein의 후임입니다. Zapata는 2022년부터 글로벌 생의학 연구 조직의 CFO로 재직한 Novartis AG 출신입니다.
제약 및 소비재 산업에서 25년 이상의 경력을 가진 Zapata는 금융, 인수합병(M&A), 디지털 전환 분야에서 폭넓은 전문 지식을 보유하고 있습니다. 그의 임명은 다제품 종양학 회사가 되려는 BioNTech의 전략과 부합합니다. 새로운 역할에서 Zapata는 금융 인프라 최적화, 주요 시장에서의 성과 향상, 비용 효율적인 가치 창출에 집중하며 종양학 제품 출시 준비를 지원할 예정입니다.
BioNTech (NASDAQ : BNTX) a nommé Ramón Zapata-Gomez en tant que nouveau Directeur Financier, à compter du 1er juillet 2025. Zapata succédera à Jens Holstein, qui prendra sa retraite comme prévu le 30 juin 2025. Zapata rejoint BioNTech en provenance de Novartis AG, où il a occupé le poste de CFO de l'organisation mondiale de recherche biomédicale depuis 2022.
Fort de plus de 25 ans d'expérience dans les industries pharmaceutique et des biens de consommation, Zapata apporte une expertise approfondie en finance, fusions-acquisitions et transformations digitales. Sa nomination s'inscrit dans la stratégie de BioNTech visant à devenir une entreprise oncologique multi-produits. Dans ses nouvelles fonctions, Zapata se concentrera sur l'optimisation de l'infrastructure financière, la performance sur les marchés clés et la génération de valeur rentable, alors que l'entreprise se prépare au lancement de produits oncologiques.
BioNTech (NASDAQ: BNTX) hat Ramón Zapata-Gomez mit Wirkung zum 1. Juli 2025 zum neuen Chief Financial Officer ernannt. Zapata wird Jens Holstein nachfolgen, der planmäßig am 30. Juni 2025 in den Ruhestand geht. Zapata kommt von Novartis AG, wo er seit 2022 als CFO der globalen biomedizinischen Forschungsorganisation tätig war.
Mit über 25 Jahren Erfahrung in der Pharma- und Konsumgüterindustrie bringt Zapata umfassende Expertise in Finanzen, Fusionen und Übernahmen sowie digitalen Transformationen mit. Seine Ernennung steht im Einklang mit BioNTechs Strategie, ein Multi-Produkt-Onkologieunternehmen zu werden. In seiner neuen Rolle wird sich Zapata darauf konzentrieren, die Finanzinfrastruktur zu optimieren, die Leistung in Schlüsselmärkten zu verbessern und eine kosteneffiziente Wertschöpfung voranzutreiben, während sich das Unternehmen auf die Markteinführung von Onkologieprodukten vorbereitet.
- Appointment of experienced CFO with 25+ years in pharmaceutical and consumer goods industries
- New CFO brings expertise in M&A transactions, integrations, and digital finance transformations
- Smooth leadership transition with planned succession
- Strategic alignment with company's vision to expand into multi-product oncology company
- None.
Mainz, Germany, May 5, 2025 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Ramón Zapata-Gomez to the Management Board as Chief Financial Officer (“CFO”) effective July 1, 2025. He will join BioNTech from Novartis AG’s global biomedical research organization where he has been serving as CFO since 2022. Ramón Zapata will succeed Jens Holstein, who, as previously planned and announced, will retire at the end of his term on June 30, 2025.
In his new role as CFO at BioNTech, Ramón Zapata will ensure the Company’s financial direction continues to align with BioNTech’s strategy to become a multi-product company in the oncology field. In preparation for BioNTech’s oncology product launches, he will be responsible for fostering and further optimizing a strong financial infrastructure and performance in key markets. He will continue to drive sustainable organizational excellence and global execution in financial reporting, accounting, tax and treasury, and purchasing with the aim of furthering cost-effective value generation.
“Ramón Zapata is an accomplished leader with deep finance expertise who will be taking over from Jens Holstein at an exciting phase. He has gained extensive experience within the international pharmaceutical industry with a focus on North America, Europe, and Latin America, and has a deep understanding of market and business dynamics, resource optimization, and high-performing teams,” said Helmut Jeggle, Chairman of the Supervisory Board. “We, the Supervisory and the Management Board, thank Jens Holstein for his financial leadership and contributions to BioNTech’s successful trajectory. He strengthened BioNTech’s global finance organization and processes and contributed to the Company’s financial stability while increasing operational efficiency. Today, the Company is uniquely positioned to continue its success story and transformation into a multi-product company.”
“It has been a privilege to be part of the development of BioNTech into one of the largest global biotechnology companies,” said Jens Holstein, CFO at BioNTech. “I would like to thank my colleagues on the Boards as well as my teams for their dedication and collaboration during this remarkable growth journey. For me personally, it is the right time to retire as CFO and focus on non-executive Board roles in the future.”
“I am looking forward to joining BioNTech and am eager to contribute to its ambitious vision of improving patients’ lives,” said Ramón Zapata, designated CFO at BioNTech. “Throughout my career, I have been driven by the goal of developing and providing access to innovative medicines for patients. As BioNTech focuses on its first oncology launches, while advancing its unique clinical pipeline with disruptive and synergistic potential, I look forward to working with the talented team at BioNTech and accelerating financial strategies that support the Company’s vision.”
Ramón Zapata is a seasoned global finance executive with more than 25 years of experience in the pharmaceutical and consumer goods industries. He has held leadership roles at leading global companies including Novartis AG, Sandoz AG, and Mondelēz International. Throughout his career, Ramón Zapata has led finance functions enabling seamless execution from drug discovery through commercialization, including overseeing M&A transactions and successful integrations as well as driving digital finance transformations. Prior to joining BioNTech, Ramón Zapata served as CFO of BioMedical Research at Novartis, where he was responsible for the overall leadership of the division’s finance strategy and operations.
Ramón Zapata holds dual citizenship of the United States and Mexico. He is a Certified Public Accountant (CPA) from Universidad Panamericana in Mexico City and holds an MBA degree from IPADE Business School in Mexico City and from IESE Business School in Barcelona, Spain.
About BioNTech
Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel investigative therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent of rapid development of novel biopharmaceuticals. Its diversified portfolio of oncology product candidates aiming to address the full continuum of cancer includes mRNA cancer immunotherapies, next-generation immunomodulators and targeted therapies such as antibody-drug conjugates (ADCs) and innovative chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house manufacturing capabilities, BioNTech and its collaborators are researching and developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genevant, Genmab, MediLink, OncoC4, Pfizer and Regeneron.
For more information, please visit www.BioNTech.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not be limited to, statements concerning: expected changes to BioNTech’s leadership and the potential benefits of BioNTech’s leadership hires; BioNTech’s research and development programs; BioNTech’s focus on building commercial capabilities for potential market launches; and BioNTech’s expectations regarding the timing of, ability to obtain and maintain regulatory approval of, and planned readiness for, such launches. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors, many of which are beyond BioNTech’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: discussions with regulatory agencies regarding timing and requirements for additional clinical trials; the ability to produce comparable clinical results in future clinical trials; competition related to BioNTech’s product candidates, including those with different mechanisms of action and different manufacturing and distribution constraints, on the basis of, among other things, efficacy, cost, convenience of storage and distribution, breadth of approved use, side-effect profile and durability of immune response; the timing of and BioNTech’s ability to obtain and maintain regulatory approval for BioNTech’s product candidates; BioNTech’s and its counterparties’ ability to manage and source necessary resources; BioNTech’s ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of BioNTech’s third-party collaborators to continue research and development activities relating to BioNTech’s development candidates and investigational medicines; BioNTech’s and its collaborators’ ability to commercialize and market its product candidates, if approved; BioNTech’s ability to manage its development and expansion; regulatory developments in the United States and other countries; BioNTech’s ability to effectively scale its production capabilities and manufacture its product candidates; and other factors not known to BioNTech at this time.
You should review the risks and uncertainties described under the heading “Risk Factors” in BioNTech's Annual Report on Form 20-F for the period ended December 31, 2024, and in subsequent filings made by BioNTech with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on BioNTech’s current expectations and speak only as of the date hereof.
CONTACTS
Media Relations
Jasmina Alatovic
Media@biontech.de
Investor Relations
Michael Horowicz
Investors@biontech.de
FAQ
Who is the new CFO of BioNTech (BNTX) and when does he start?
Why is BioNTech (BNTX) changing its CFO in 2025?
What is Ramón Zapata's background before joining BioNTech (BNTX)?
What will be the main responsibilities of BioNTech's (BNTX) new CFO?
